The clinicaltrials.gov listings for SAKURA-1/2 have always said completion was expected in Dec 2017, so I don't see any reason to question the integrity of RVNC's behavior.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.